EXEL
Exelixis, Inc.
Price Chart
Latest Quote
$42.81
Current Price| Previous Close | $41.36 |
| Open | $41.85 |
| Day High | $42.83 |
| Day Low | $40.54 |
| Volume | 4,145,738 |
Stock Information
| Shares Outstanding | 268.11M |
| Total Debt | $176.46M |
| Cash Equivalents | $988.53M |
| Revenue | $2.29B |
| Net Income | $677.90M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $11.52B |
| P/E Ratio | 17.99 |
| EPS (TTM) | $2.38 |
| Exchange | NMS |
đ Custom Metrics & Score
Score: 28/42| Debt to Equity | 0.09 |
| Debt to Earnings | 0.09 |
| Current Ratio | 3.63 |
| Quick Ratio | 3.41 |
| Avg Revenue Growth | 12.78% |
| Profit Margin | 24.04% |
| Return on Equity | 23.23% |
| Avg FCF Growth | 22.08% |
| FCF Yield | 5.50% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $42.81 | 4,145,738 |
| 2026-01-30 | $41.36 | 3,436,000 |
| 2026-01-29 | $42.28 | 3,116,000 |
| 2026-01-28 | $42.66 | 2,330,200 |
| 2026-01-27 | $43.74 | 1,925,100 |
| 2026-01-26 | $43.61 | 2,263,500 |
| 2026-01-23 | $44.27 | 2,117,500 |
| 2026-01-22 | $44.50 | 2,202,300 |
| 2026-01-21 | $44.81 | 2,007,900 |
| 2026-01-20 | $43.78 | 1,662,800 |
| 2026-01-16 | $43.96 | 2,898,500 |
| 2026-01-15 | $45.44 | 2,268,800 |
| 2026-01-14 | $45.23 | 1,722,700 |
| 2026-01-13 | $44.08 | 2,082,400 |
| 2026-01-12 | $44.06 | 4,143,000 |
| 2026-01-09 | $44.04 | 2,830,800 |
| 2026-01-08 | $44.15 | 2,728,800 |
| 2026-01-07 | $46.19 | 2,543,800 |
| 2026-01-06 | $43.68 | 2,381,800 |
| 2026-01-05 | $42.40 | 2,916,500 |
About Exelixis, Inc.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
đ° Latest News
Is It Too Late To Consider Exelixis (EXEL) After Strong Multi Year Share Gains?
Simply Wall St. âĸ 2026-02-02T07:07:49Z
Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential
Simply Wall St. âĸ 2026-02-02T01:07:17Z
Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility
Simply Wall St. âĸ 2026-02-01T15:10:15Z
Is Exelixis (EXEL) Using Zanzalintinib To Redefine Its Post-Cabometyx Oncology Strategy?
Simply Wall St. âĸ 2026-02-01T12:07:52Z
2 Stocks That Could Soar This Year
Motley Fool âĸ 2026-02-01T00:13:00Z
Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies
Pharmaceutical Technology âĸ 2026-01-28T10:42:16Z
EXEL vs. EXAS: Which Stock Is the Better Value Option?
Zacks âĸ 2026-01-27T16:40:04Z
How The New Price Target Is Shaping The Exelixis (EXEL) Investment Story
Simply Wall St. âĸ 2026-01-22T10:10:33Z
Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch
Insider Monkey âĸ 2026-01-20T09:59:54Z
Exelixis, Inc. (EXEL): A Bull Case Theory
Insider Monkey âĸ 2026-01-15T20:01:24Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $76,216,000 | $72,547,000 | $57,909,000 | $52,873,000 |
| Cost Of Revenue | $76,216,000 | $72,547,000 | $57,909,000 | $52,873,000 |
| Total Revenue | $2,168,701,000 | $1,830,208,000 | $1,611,062,000 | $1,434,970,000 |
| Operating Revenue | $2,877,552,000 | $2,473,862,000 | $2,160,988,000 | $1,810,627,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $1,478,752,000 | $1,659,323,000 | $1,409,578,000 | $1,148,304,000 |
| Other Income Expense | $-85,465,000 | $93,000 | $-197,000 | $-184,000 |
| Other Non Operating Income Expenses | $-133,000 | $93,000 | $-197,000 | $-184,000 |
| Net Non Operating Interest Income Expense | $77,156,000 | $86,543,000 | $33,065,000 | $7,672,000 |
| Operating Expense | $1,402,536,000 | $1,586,776,000 | $1,351,669,000 | $1,095,431,000 |
| General And Administrative Expense | $492,128,000 | $542,705,000 | - | - |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $521,267,000 | $207,765,000 | $182,282,000 | $231,063,000 |
| Net Interest Income | $77,156,000 | $86,543,000 | $33,065,000 | $7,672,000 |
| Interest Income | $77,156,000 | $86,543,000 | $33,065,000 | $7,672,000 |
| Normalized Income | $586,545,980 | $207,765,000 | $182,282,000 | $231,063,000 |
| Net Income From Continuing And Discontinued Operation | $521,267,000 | $207,765,000 | $182,282,000 | $231,063,000 |
| Total Operating Income As Reported | $604,617,000 | $170,885,000 | $201,484,000 | $286,666,000 |
| Net Income Common Stockholders | $521,267,000 | $207,765,000 | $182,282,000 | $231,063,000 |
| Net Income | $521,267,000 | $207,765,000 | $182,282,000 | $231,063,000 |
| Net Income Including Noncontrolling Interests | $521,267,000 | $207,765,000 | $182,282,000 | $231,063,000 |
| Net Income Continuous Operations | $521,267,000 | $207,765,000 | $182,282,000 | $231,063,000 |
| Pretax Income | $681,640,000 | $257,521,000 | $234,352,000 | $294,154,000 |
| Special Income Charges | $-85,332,000 | $0 | $0 | - |
| Interest Income Non Operating | $77,156,000 | $86,543,000 | $33,065,000 | $7,672,000 |
| Operating Income | $689,949,000 | $170,885,000 | $201,484,000 | $286,666,000 |
| Gross Profit | $2,092,485,000 | $1,757,661,000 | $1,553,153,000 | $1,382,097,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $1.76 | $0.65 | $0.56 | $0.72 |
| Basic EPS | $1.80 | $0.65 | $0.56 | $0.73 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-20,053,020 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $804,084,000 | $196,602,000 | $222,359,000 | $300,296,000 |
| Total Unusual Items | $-85,332,000 | $0 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-85,332,000 | $0 | $0 | - |
| Reconciled Depreciation | $28,803,000 | $25,717,000 | $20,875,000 | $13,630,000 |
| EBITDA (Bullshit earnings) | $718,752,000 | $196,602,000 | $222,359,000 | $300,296,000 |
| EBIT | $689,949,000 | $170,885,000 | $201,484,000 | $286,666,000 |
| Diluted Average Shares | $296,132,000 | $321,464,000 | $324,556,000 | $322,359,000 |
| Basic Average Shares | $290,030,000 | $318,151,000 | $324,556,000 | $314,884,000 |
| Diluted NI Availto Com Stockholders | $521,267,000 | $207,765,000 | $182,282,000 | $231,063,000 |
| Tax Provision | $160,373,000 | $49,756,000 | $52,070,000 | $63,091,000 |
| Impairment Of Capital Assets | $64,391,000 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $20,941,000 | $0 | $0 | - |
| Research And Development | $910,408,000 | $1,044,071,000 | $891,813,000 | $693,716,000 |
| Selling General And Administration | $492,128,000 | $542,705,000 | $459,856,000 | $401,715,000 |
| Other Gand A | $428,962,000 | $470,680,000 | - | - |
| Salaries And Wages | $63,166,000 | $72,025,000 | - | - |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $2,180,519,000 | $2,200,228,000 | $2,424,743,000 | $2,146,931,000 |
| Total Assets | $2,947,690,000 | $2,942,357,000 | $3,071,489,000 | $2,616,239,000 |
| Total Non Current Assets | $1,480,111,000 | $1,624,399,000 | $1,452,727,000 | $781,492,000 |
| Non Current Deferred Assets | $420,027,000 | $361,145,000 | $231,110,000 | $111,663,000 |
| Non Current Deferred Taxes Assets | $420,027,000 | $361,145,000 | $231,110,000 | $111,663,000 |
| Goodwill And Other Intangible Assets | $63,684,000 | $63,684,000 | $63,684,000 | $63,684,000 |
| Current Assets | $1,467,579,000 | $1,317,958,000 | $1,618,762,000 | $1,834,747,000 |
| Other Current Assets | $68,478,000 | $67,926,000 | $62,211,000 | $57,530,000 |
| Inventory | $22,388,000 | $17,323,000 | $33,299,000 | $27,493,000 |
| Receivables | $265,437,000 | $237,407,000 | $214,784,000 | $282,650,000 |
| Accounts Receivable | $265,437,000 | $237,407,000 | $214,784,000 | $282,650,000 |
| Cash Cash Equivalents And Short Term Investments | $1,111,276,000 | $995,302,000 | $1,308,468,000 | $1,467,074,000 |
| Cash And Cash Equivalents | $217,374,000 | $262,994,000 | $501,195,000 | $647,169,000 |
| Other Non Current Assets | - | - | - | $131,002,000 |
| Prepaid Assets | - | - | - | $57,530,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $190,823,000 | $189,944,000 | $190,170,000 | $51,272,000 |
| Long Term Debt And Capital Lease Obligation | $190,823,000 | $189,944,000 | $190,170,000 | $51,272,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $703,487,000 | $678,445,000 | $583,062,000 | $405,624,000 |
| Total Non Current Liabilities Net Minority Interest | $299,718,000 | $284,168,000 | $258,703,000 | $68,034,000 |
| Other Non Current Liabilities | $108,895,000 | $94,224,000 | $68,533,000 | $8,023,000 |
| Current Liabilities | $403,769,000 | $394,277,000 | $324,359,000 | $337,590,000 |
| Other Current Liabilities | $95,012,000 | $108,417,000 | $78,924,000 | $53,366,000 |
| Payables And Accrued Expenses | $136,551,000 | $132,916,000 | $117,927,000 | $188,555,000 |
| Payables | $38,191,000 | $33,768,000 | $32,667,000 | $24,258,000 |
| Accounts Payable | $38,191,000 | $33,768,000 | $32,667,000 | $24,258,000 |
| Non Current Deferred Liabilities | - | - | $6,582,000 | $8,739,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 | $2,210,615,000 |
| Total Equity Gross Minority Interest | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 | $2,210,615,000 |
| Stockholders Equity | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 | $2,210,615,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,347,000 | $-3,750,000 | $-14,521,000 | $-758,000 |
| Other Equity Adjustments | $-1,347,000 | $-3,750,000 | $-14,521,000 | $-758,000 |
| Retained Earnings | $-98,647,000 | $-173,351,000 | $-34,225,000 | $-216,507,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $281,732,000 | $302,793,000 | $323,951,000 | $318,842,000 |
| Share Issued | $281,732,000 | $302,793,000 | $323,951,000 | $318,842,000 |
| Tangible Book Value | $2,180,519,000 | $2,200,228,000 | $2,424,743,000 | $2,146,931,000 |
| Invested Capital | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 | $2,210,615,000 |
| Working Capital | $1,063,810,000 | $923,681,000 | $1,294,403,000 | $1,497,157,000 |
| Capital Lease Obligations | $190,823,000 | $189,944,000 | $190,170,000 | $51,272,000 |
| Total Capitalization | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 | $2,210,615,000 |
| Additional Paid In Capital | $2,343,915,000 | $2,440,710,000 | $2,536,849,000 | $2,427,561,000 |
| Capital Stock | $282,000 | $303,000 | $324,000 | $319,000 |
| Common Stock | $282,000 | $303,000 | $324,000 | $319,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $190,823,000 | $189,944,000 | $190,170,000 | $51,272,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $109,830,000 | $93,325,000 | $77,158,000 | $61,969,000 |
| Current Provisions | $62,376,000 | $59,619,000 | $50,350,000 | $33,700,000 |
| Current Accrued Expenses | $98,360,000 | $99,148,000 | $85,260,000 | $164,297,000 |
| Investments And Advances | $637,291,000 | $728,717,000 | $756,731,000 | $371,112,000 |
| Goodwill | $63,684,000 | $63,684,000 | $63,684,000 | $63,684,000 |
| Net PPE | $359,109,000 | $470,853,000 | $401,202,000 | $235,033,000 |
| Accumulated Depreciation | $-100,732,000 | $-80,390,000 | $-60,872,000 | $-40,831,000 |
| Gross PPE | $459,841,000 | $551,243,000 | $462,074,000 | $275,864,000 |
| Leases | $108,277,000 | $89,038,000 | $83,334,000 | $73,589,000 |
| Construction In Progress | $2,875,000 | $24,465,000 | $4,933,000 | $16,872,000 |
| Other Properties | $310,153,000 | $393,026,000 | $330,184,000 | $154,746,000 |
| Machinery Furniture Equipment | $38,536,000 | $44,714,000 | $43,623,000 | $30,657,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $893,902,000 | $732,308,000 | $807,273,000 | $819,905,000 |
| Non Current Deferred Revenue | - | - | $6,582,000 | $8,739,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $633,786,000 | $170,355,000 | $224,158,000 | $336,579,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $699,971,000 | $333,324,000 | $362,614,000 | $400,804,000 |
| Cash Flow From Continuing Operating Activities | $699,971,000 | $333,324,000 | $362,614,000 | $400,804,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-66,185,000 | $-162,969,000 | $-138,456,000 | $-64,225,000 |
| Investing Cash Flow | $-116,783,000 | $-26,955,000 | $-524,414,000 | $-42,884,000 |
| Cash Flow From Continuing Investing Activities | $-116,783,000 | $-26,955,000 | $-524,414,000 | $-42,884,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-652,033,000 | $-550,378,000 | $0 | $0 |
| Financing Cash Flow | $-628,808,000 | $-546,052,000 | $586,000 | $-14,801,000 |
| Cash Flow From Continuing Financing Activities | $-628,808,000 | $-546,052,000 | $586,000 | $-14,801,000 |
| Net Other Financing Charges | $-38,625,000 | $-29,122,000 | $-23,300,000 | $-39,108,000 |
| Net Common Stock Issuance | $-652,033,000 | $-550,378,000 | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Income Tax Paid Supplemental Data | $170,482,000 | $185,658,000 | $127,870,000 | $12,960,000 |
| End Cash Position | $217,374,000 | $262,994,000 | $502,677,000 | $663,891,000 |
| Beginning Cash Position | $262,994,000 | $502,677,000 | $663,891,000 | $320,772,000 |
| Changes In Cash | $-45,620,000 | $-239,683,000 | $-161,214,000 | $343,119,000 |
| Proceeds From Stock Option Exercised | $61,850,000 | $33,448,000 | $23,886,000 | $24,307,000 |
| Common Stock Payments | $-652,033,000 | $-550,378,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-50,598,000 | $136,014,000 | $-385,958,000 | $21,341,000 |
| Sale Of Investment | $877,307,000 | $1,038,482,000 | $1,064,758,000 | $1,378,509,000 |
| Purchase Of Investment | $-927,905,000 | $-902,468,000 | $-1,450,716,000 | $-1,357,168,000 |
| Net Intangibles Purchase And Sale | $-37,750,000 | $-122,500,000 | $-110,750,000 | $-10,000,000 |
| Purchase Of Intangibles | $-37,750,000 | $-122,500,000 | $-110,750,000 | $-10,000,000 |
| Net PPE Purchase And Sale | $-28,435,000 | $-40,469,000 | $-27,706,000 | $-54,225,000 |
| Purchase Of PPE | $-28,435,000 | $-40,469,000 | $-27,706,000 | $-54,225,000 |
| Change In Working Capital | $-13,453,000 | $-13,973,000 | $-12,799,000 | $-39,013,000 |
| Change In Payables And Accrued Expense | $-22,035,000 | $51,451,000 | $-39,706,000 | $125,387,000 |
| Change In Accrued Expense | $-149,000 | $1,345,000 | $-63,065,000 | $70,297,000 |
| Change In Payable | $-21,886,000 | $50,106,000 | $23,359,000 | $55,090,000 |
| Change In Account Payable | $-21,886,000 | $50,106,000 | $23,359,000 | $55,090,000 |
| Change In Prepaid Assets | $31,079,000 | $-29,824,000 | $-28,259,000 | $-39,875,000 |
| Change In Inventory | $5,453,000 | $-12,977,000 | $-11,683,000 | $-13,209,000 |
| Change In Receivables | $-27,950,000 | $-22,623,000 | $66,849,000 | $-122,324,000 |
| Changes In Account Receivables | $-27,950,000 | $-22,623,000 | $66,849,000 | $-122,324,000 |
| Other Non Cash Items | $64,585,000 | $140,679,000 | $125,040,000 | $28,775,000 |
| Stock Based Compensation | $93,836,000 | $106,345,000 | $107,574,000 | $119,820,000 |
| Asset Impairment Charge | $64,391,000 | $0 | $0 | - |
| Deferred Tax | $-59,458,000 | $-133,209,000 | $-60,358,000 | $46,529,000 |
| Deferred Income Tax | $-59,458,000 | $-133,209,000 | $-60,358,000 | $46,529,000 |
| Depreciation Amortization Depletion | $28,803,000 | $25,717,000 | $20,875,000 | $13,630,000 |
| Depreciation And Amortization | $28,803,000 | $25,717,000 | $20,875,000 | $13,630,000 |
| Net Income From Continuing Operations | $521,267,000 | $207,765,000 | $182,282,000 | $231,063,000 |
| Change In Other Working Capital | - | $-3,140,000 | $-2,483,000 | $11,008,000 |
| Depreciation | - | $25,717,000 | $20,875,000 | $13,630,000 |